Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6234 in Overweight or Obesity
NCT06132841Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of lenbelintide in obesity (4 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of participants with Adverse Events and Serious Adverse Events at Day 225. Started Nov 2023; status: completed.
02
Drugs
lenbelintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06132841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132841.